OmniAb, Inc. (NASDAQ: OABI)

OmniAb, Inc., a biotechnology company, operates under the stock symbol OMNI on the NASDAQ exchange. The company specializes in the field of discovery research technology, offering solutions to the pharmaceutical and biotech industry for the development of next-generation therapeutics.

The core of OmniAb's business revolves around its proprietary technology platform, which encompasses a range of integrated technologies designed to streamline and enhance the antibody discovery process. A significant aspect of this platform is the use of transgenic animals, such as OmniRat, OmniMouse, and OmniChicken, which have been genetically modified to produce antibodies with human sequences. These animals facilitate the generation of high-quality antibodies even in the face of complex biological challenges.

Additionally, the OmniAb platform incorporates advanced screening technologies, including xPloration and Gel Encapsulated Microenvironment (GEM). These technologies leverage artificial intelligence and machine learning algorithms to rapidly identify thousands of therapeutic antibody candidates, thereby accelerating the discovery process and reducing associated costs.

Compared to traditional antibody discovery methods, OmniAb's technology offers several advantages. For instance, the use of transgenic animals that generate antibodies with human sequences eliminates the need for antibody optimization and minimizes the risk of immunogenicity and toxicity. Furthermore, the company's advanced screening technologies enable the swift identification of thousands of therapeutic antibody candidates, significantly cutting down on the time and resources required by traditional methods.

OmniAb's business model is primarily based on partnerships with pharmaceutical and biotech companies, as well as leading academic institutions. Through these collaborations, partners gain access to OmniAb's proprietary technology and expertise, and OmniAb receives upfront payments, milestone payments, and royalties on net sales of its partners' products. As of December 31, 2023, OmniAb boasted 77 active partners with 325 active programs utilizing the OmniAb technology platform. The success of the company's technology is evident in the 28 OmniAb-derived antibodies in clinical development, one under regulatory review, and three approved products.

The antibody therapeutics market is experiencing robust growth, with monoclonal antibodies accounting for the majority of the top 10 bestselling drugs over the past five years. This trend is expected to continue, with Clarivate Analytics Cortellis predicting that antibody-based therapeutic sales will surpass $300 billion by 2027. OmniAb is well-positioned to capitalize on this market opportunity, with a unique technology platform that provides several advantages over traditional antibody discovery methods and a strong track record of delivering high-quality antibodies for therapeutic applications.